Copper

證據等級: L5

預測適應症: 10 個

Copper: From Copper Deficiency to Esotropia

One-Sentence Summary

Copper (DrugBank DB09130) is an essential trace element used primarily to address copper deficiency states, functioning as a cofactor for multiple critical metalloenzymes in human physiology. The TxGNN model predicts it may be effective for Esotropia (convergent strabismus caused by extraocular muscle imbalance), with 0 clinical trials and 0 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Copper deficiency
Predicted New Indication	Esotropia
TxGNN Prediction Score	96.25%
Evidence Level	L5
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Copper is an essential trace element that functions as a catalytic cofactor for several key metalloenzymes: lysyl oxidase (responsible for collagen and elastin cross-linking in connective tissue), tyrosinase (involved in melanin biosynthesis), ceruloplasmin (iron metabolism and antioxidant defense), and copper-zinc superoxide dismutase (Cu-Zn SOD, a primary cellular antioxidant). These roles position copper as biologically relevant to tissue maintenance, oxidative stress regulation, and wound healing processes.

However, the connection between copper and esotropia is not biologically established. Esotropia is characterised by inward deviation of one or both eyes due to extraocular muscle imbalance or defective neural control of eye alignment. Standard treatments include optical correction (prism lenses), occlusion therapy, botulinum toxin injection, or surgical muscle repositioning — none of which involve trace element modulation. There is no known biochemical pathway by which systemic copper status would directly influence extraocular muscle tone or the neural circuitry governing binocular alignment.

Detailed mechanism of action data is not currently available from DrugBank. Based on the model's own assessment, the high TxGNN prediction score (96.25%) likely reflects topological proximity within the ophthalmology disease cluster in the knowledge graph rather than direct biological plausibility. This prediction should be interpreted with significant caution and is not considered actionable without a clearly articulated mechanistic hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: There are zero clinical trials and zero published studies supporting the use of copper for esotropia, and no established mechanistic link exists between copper biology and extraocular muscle imbalance. The high TxGNN score reflects knowledge graph topology rather than biological plausibility, making this a model artefact rather than a genuine repurposing signal.

To proceed, the following is needed:

Develop a biologically plausible mechanistic hypothesis linking copper homeostasis to extraocular muscle function or oculomotor neural control
Obtain complete MOA and safety data from DrugBank (DG001, DG002) before any further evaluation
Conduct a targeted literature search in ophthalmology and neuromuscular physiology to identify any indirect copper-related pathways (e.g., Cu-Zn SOD in ocular tissue, copper's role in neurological conditions affecting eye movement)
Consider deprioritising this indication in favour of Rank 2 (Dermatitis, L4 evidence) or Rank 8 (Dry Eye Syndrome, L4 evidence), both of which have a more mechanistically coherent rationale and existing — albeit early-stage — experimental data

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.